$BFRI
Biofrontera Inc Stock $bfri

$bfri Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223007472 Filed on March 13, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$8.733M	$10.14M	$28.67M
YoY Change	-10.44%	10.65%	18.98%
Cost Of Revenue	$4.598M	$5.256M	$15.19M
YoY Change	-10.72%	10.12%	19.17%
Gross Profit	$4.135M	$4.888M	$13.49M
YoY Change	-10.13%	11.22%	18.76%
Gross Profit Margin	47.35%	48.19%	47.04%
Selling, General & Admin	$9.800M	$10.21M	$35.14M
YoY Change	27.09%	10.04%	35.99%
% of Gross Profit	237.0%	208.84%	260.49%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$22.00K	$125.0K	$100.0K
YoY Change	-83.21%	-4.58%	-81.48%
% of Gross Profit	0.53%	2.56%	0.74%
Operating Expenses	$14.23M	$10.51M	$47.26M
YoY Change	84.48%	70.11%	92.43%
Operating Profit	-$5.500M	-$5.620M	-$18.58M
YoY Change	76.85%	215.38%	40.78%
Interest Expense	$2.000K	-$35.00K	$195.0K
YoY Change	-106.06%	-60.67%	-156.69%
% of Operating Profit
Other Income/Expense, Net	-$1.981M	$2.871M	$17.97M
YoY Change	-122.68%	-122.91%	-248.39%
Pretax Income	-$7.473M	-$2.784M	-$608.0K
YoY Change	-233.66%	-80.8%	-98.39%
Income Tax	$5.000K	$1.000K	$32.00K
% Of Pretax Income
Net Earnings	-$7.478M	-$2.785M	-$640.0K
YoY Change	-234.47%	-80.8%	-98.3%
Net Earnings / Revenue	-85.63%	-27.45%	-2.23%
Basic Earnings Per Share	-$0.28		-$0.03
Diluted Earnings Per Share	-$0.28	-$0.11	-$0.03
COMMON SHARES
Basic Shares Outstanding	26.70M shares	26.70M shares	21.14M shares
Diluted Shares Outstanding	26.70M shares		1.057M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.10M	$27.84M	$27.84M
YoY Change	-6.45%	12.74%	12.74%
Cash & Equivalents	$13.51M	$17.21M	$17.21M
Short-Term Investments	$7.596M	$10.63M	$10.63M
Other Short-Term Assets	$1.586M	$725.0K	$725.0K
YoY Change	27.39%	-85.01%	-85.01%
Inventory	$6.670M	$7.168M	$7.168M
Prepaid Expenses		$439.0K
Receivables	$7.866M	$7.406M	$7.406M
Other Receivables	$3.750M	$0.00	$0.00
Total Short-Term Assets	$37.22M	$43.14M	$43.14M
YoY Change	-12.48%	-7.07%	-7.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$197.0K	$204.0K	$1.579M
YoY Change	-19.59%	-23.6%	491.39%
Goodwill
YoY Change
Intangibles	$2.927M	$3.032M
YoY Change		-12.12%
Long-Term Investments
YoY Change
Other Assets	$384.0K	$320.0K	$320.0K
YoY Change	43.28%	19.4%	19.4%
Total Long-Term Assets	$4.742M	$7.744M	$7.744M
YoY Change	-28.92%	13.92%	13.92%
TOTAL ASSETS
Total Short-Term Assets	$37.22M	$43.14M	$43.14M
Total Long-Term Assets	$4.742M	$7.744M	$7.744M
Total Assets	$41.97M	$50.88M	$50.88M
YoY Change	-14.71%	-4.39%	-4.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$887.0K	$1.278M	$2.590M
YoY Change	55.34%	94.22%	175.53%
Accrued Expenses	$11.14M	$10.86M	$10.99M
YoY Change	42.41%	12.53%	24.53%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.45M	$20.89M	$20.89M
YoY Change	65.47%	51.01%	51.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$24.00K	$21.00K	$6.112M
YoY Change	-99.88%	-99.63%	-78.21%
Total Long-Term Liabilities	$24.00K	$21.00K	$6.112M
YoY Change	-99.88%	-99.63%	-78.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.45M	$20.89M	$20.89M
Total Long-Term Liabilities	$24.00K	$21.00K	$6.112M
Total Liabilities	$25.21M	$27.01M	$27.01M
YoY Change	-20.68%	-35.52%	-35.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$87.00M	-$79.50M
YoY Change		0.79%
Common Stock	$27.00K	$27.00K
YoY Change		58.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.75M	$23.88M	$23.88M
YoY Change
Total Liabilities & Shareholders Equity	$41.97M	$50.88M	$50.88M
YoY Change	-14.71%	-4.39%	-4.39%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$7.478M	-$2.785M	-$640.0K
YoY Change	-234.47%	-80.8%	-98.3%
Depreciation, Depletion And Amortization	$22.00K	$125.0K	$100.0K
YoY Change	-83.21%	-4.58%	-81.48%
Cash From Operating Activities	-$3.700M	-$8.271M	-$16.20M
YoY Change	75.19%	-60.6%	-39.36%
INVESTING ACTIVITIES
Capital Expenditures	$14.00K	$1.000K	$38.00K
YoY Change	-380.0%	-111.11%	-445.45%
Acquisitions
YoY Change
Other Investing Activities		-$2.085M	-$5.118M
YoY Change
Cash From Investing Activities	-$14.00K	-$2.086M	-$5.156M
YoY Change	180.0%	23077.78%	46772.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	$14.02M
YoY Change		-100.0%	-67.54%
NET CHANGE
Cash From Operating Activities	-$3.700M	-8.271M	-$16.20M
Cash From Investing Activities	-$14.00K	-2.086M	-$5.156M
Cash From Financing Activities		0.000	$14.02M
Net Change In Cash	-$3.703M	-10.36M	-$7.334M
YoY Change	74.92%	-145.37%	-144.54%
FREE CASH FLOW
Cash From Operating Activities	-$3.700M	-$8.271M	-$16.20M
Capital Expenditures	$14.00K	$1.000K	$38.00K
Free Cash Flow	-$3.714M	-$8.272M	-$16.24M
YoY Change	76.27%	-60.57%	-39.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001858685
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Restructuring Charges RestructuringCharges		usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2021	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2021	BFRI	Addition Of Rightofuse Assets In Exchange For Operating Lease Liabilities AdditionOfRightofuseAssetsInExchangeForOperatingLeaseLiabilities		usd
CY2022	BFRI	Issuance Costs Included In Accrued Expenses And Other Liabilities IssuanceCostsIncludedInAccruedExpensesAndOtherLiabilities		usd
CY2022	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired		usd
CY2020Q4	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant		usd
CY2022Q4	BFRI	Receivable For Common Stock Warrants Proceeds ReceivableForCommonStockWarrantsProceeds		usd
CY2022Q4	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent		usd
CY2022Q4	BFRI	Legal Settlement Expenses LegalSettlementExpenses		usd
CY2021	BFRI	Effective Income Tax Rate Reconciliation Trueups EffectiveIncomeTaxRateReconciliationTrueups		pure
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost		usd
CY2021Q4	BFRI	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability		usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2021Q4	BFRI	Deferred Tax Assets Right Of Use Asset DeferredTaxAssetsRightOfUseAsset		usd
CY2021Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2020Q4	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2021	us-gaap	Interest Income Related Party InterestIncomeRelatedParty		usd
CY2022	BFRI	Reimbursed Costs ReimbursedCosts		usd
CY2022Q4	BFRI	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40943
CY2022	dei	Entity Registrant Name EntityRegistrantName	BIOFRONTERA INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3765675
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	120 Presidential Way
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 330
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Woburn
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01801
CY2022	dei	City Area Code CityAreaCode	(781)
CY2022	dei	Local Phone Number LocalPhoneNumber	245-1325
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	35400000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26699002	shares
CY2022	dei	Auditor Firm AuditorFirmId	248
CY2022	dei	Auditor Name AuditorName	GRANT THORNTON LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17208000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24545000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	10548000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	3748000	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	3784000	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	3658000	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	8647000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	7168000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4458000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	810000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4987000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	43140000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	46421000	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties Noncurrent AccountsReceivableRelatedPartiesNoncurrent	2813000	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Noncurrent AccountsReceivableRelatedPartiesNoncurrent	2813000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	204000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	267000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1375000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3032000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3450000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	320000	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	268000	usd
CY2022Q4	us-gaap	Assets Assets	50884000	usd
CY2021Q4	us-gaap	Assets Assets	53219000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1278000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	658000	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1312000	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	282000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	6942000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	3242000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	498000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10864000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9654000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20894000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13836000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2400000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9542000	usd
CY2022Q4	BFRI	Warrant Liabilities Non Current WarrantLiabilitiesNonCurrent	2843000	usd
CY2021Q4	BFRI	Warrant Liabilities Non Current WarrantLiabilitiesNonCurrent	12854000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	848000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5649000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	27006000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	41881000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26699002	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26699002	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17104749	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17104749	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	103370000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	90200000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79519000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78879000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23878000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11338000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50884000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53219000	usd
CY2022	BFRI	Products Revenues Net ProductsRevenuesNet	28541000	usd
CY2021	BFRI	Products Revenues Net ProductsRevenuesNet	24043000	usd
CY2022	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	133000	usd
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	57000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28674000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24100000	usd
CY2022	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	14618000	usd
CY2021	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	12222000	usd
CY2022	BFRI	Cost Of Revenues CostOfRevenues	567000	usd
CY2021	BFRI	Cost Of Revenues CostOfRevenues	520000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35137000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	36512000	usd
CY2022	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	733000	usd
CY2021	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	697000	usd
CY2021	us-gaap	Restructuring Charges RestructuringCharges	752000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3800000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1402000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	47255000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	49301000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18581000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-25201000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-16388000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	12801000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	1747000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-195000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-344000	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	33000	usd
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	689000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17973000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12456000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-608000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37657000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	56000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-640000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-37713000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.28
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21139765	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8808233	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5828000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14943000	usd
CY2021	BFRI	Stock Issued During Period Value Private Placement Offering StockIssuedDuringPeriodValuePrivatePlacementOffering	2690000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13238000	usd
CY2021	BFRI	Stock Issued During Period Value Exercise Of Prefunded Warrants StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants	12223000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	129000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-37713000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11338000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3683000	usd
CY2022	BFRI	Stock Issued During Period Value Private Placement Offering StockIssuedDuringPeriodValuePrivatePlacementOffering	117000	usd
CY2022	BFRI	Stock Issued During Period Value Exercise Of Prefunded Warrants StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants	2842000	usd
CY2022	BFRI	Stock Issued During Period Value Exercise Of Pipe Warrants StockIssuedDuringPeriodValueExerciseOfPipeWarrants	4686000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1852000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-640000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23878000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-640000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-37713000	usd
CY2022	us-gaap	Depreciation Depreciation	101000	usd
CY2021	us-gaap	Depreciation Depreciation	122000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	653000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	418000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	418000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1747000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3800000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1402000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-16388000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	12801000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1852000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	129000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	100000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	33000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	106000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	44000	usd
CY2022	BFRI	Noncash Interest Expense NoncashInterestExpense	358000	usd
CY2021	BFRI	Noncash Interest Expense NoncashInterestExpense	358000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	70000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	612000	usd
CY2022	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	-4990000	usd
CY2021	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	11387000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-4154000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	3809000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2810000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2592000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	912000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-773000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-781000	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-3607000	usd
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	12484000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16199000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26715000	usd
CY2022	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	5118000	usd
CY2022	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	38000	usd
CY2021	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	11000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5156000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14943000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9391000	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	14995000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4630000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	13253000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14021000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	43191000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7334000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16465000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24742000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8277000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17408000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24742000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	32000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	56000	usd
CY2022	BFRI	Conversion Of Warrant Liability To Equity In Connection With Exercise Of Warrants ConversionOfWarrantLiabilityToEquityInConnectionWithExerciseOfWarrants	6840000	usd
CY2021	BFRI	Conversion Of Warrant Liability To Equity In Connection With Exercise Of Warrants ConversionOfWarrantLiabilityToEquityInConnectionWithExerciseOfWarrants	12208000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	3683000	usd
CY2022	BFRI	Addition Of Rightofuse Assets In Exchange For Operating Lease Liabilities AdditionOfRightofuseAssetsInExchangeForOperatingLeaseLiabilities	234000	usd
CY2021	BFRI	Issuance Costs Included In Accrued Expenses And Other Liabilities IssuanceCostsIncludedInAccruedExpensesAndOtherLiabilities	44000	usd
CY2021	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	8000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9400000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17200000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24500000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-600000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-37700000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16200000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26700000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79500000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2500000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2400000	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	6200000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zTsjg57U9vba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zkYC8G9J2q2h">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions by management that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities, as reported on the balance sheet date, and the reported amounts of revenues and expenses arising during the reporting period. The main areas in which assumptions, estimates and the exercising of judgment are appropriate relate to valuation allowances for receivables and inventory, valuation of contingent consideration and warrant liabilities, realization of intangible and other long-lived assets, product sales allowances and reserves, share-based payments and income taxes including deferred tax assets and liabilities. Estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances. They are continuously reviewed but may vary from the actual values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p>
CY2022Q4	BFRI	Startup Cost Financing StartupCostFinancing	7300000	usd
CY2021Q4	BFRI	Startup Cost Financing StartupCostFinancing	7300000	usd
CY2022Q4	BFRI	Contract Asset ContractAsset	-358000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zEZJyuVmSXEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zoqyq0nojKy">Concentration of Credit Risk and Off-Balance Sheet Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, accounts receivable and other receivables, related party. The Company maintains all of its cash and cash equivalents at a single accredited financial institution, in amounts that exceed federally insured limits. The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers using our products. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ConcentrationRiskLicense_c20220101__20221231_zVGxEOwaqtak" title="Concentration risk license, descriptions">Other receivables, related party consists of a receivable due from Biofrontera AG for its 50% share of a legal settlement and related costs for which they are jointly and severally liable for the total settlement amount. The Company has a contractual right to repayment of its share of the settlement payment from Biofrontera AG under the Settlement Allocation Agreement entered into on December 9, 2021, which provided that the settlement payments would first be made by the Company and then reimbursed by Biofrontera AG for its share. Although this receivable has credit risk, it is mitigated by the Settlement Allocation Agreement as amended on March 31, 2022, which provides certain remedies to the Company, if Biofrontera AG fails to make timely reimbursements, which the Company may implement in its sole discretion, including the ability to charge interest at a rate of 6.0% per annum for each day that any reimbursement is past due and the ability to offset any overdue reimbursement amounts against payments owed to Biofrontera AG by the Company</span> (including amounts owed under the Company’s license and supply agreement for Ameluz<sup>®</sup>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are dependent on two suppliers, Biofrontera Pharma GmbH and Ferrer Internacional S.A., to supply drug products, including all underlying components, for our commercial efforts. These efforts could be adversely affected by a significant interruption in the supply of our finished products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Concentration Risk License ConcentrationRiskLicense	Other receivables, related party consists of a receivable due from Biofrontera AG for its 50% share of a legal settlement and related costs for which they are jointly and severally liable for the total settlement amount. The Company has a contractual right to repayment of its share of the settlement payment from Biofrontera AG under the Settlement Allocation Agreement entered into on December 9, 2021, which provided that the settlement payments would first be made by the Company and then reimbursed by Biofrontera AG for its share. Although this receivable has credit risk, it is mitigated by the Settlement Allocation Agreement as amended on March 31, 2022, which provides certain remedies to the Company, if Biofrontera AG fails to make timely reimbursements, which the Company may implement in its sole discretion, including the ability to charge interest at a rate of 6.0% per annum for each day that any reimbursement is past due and the ability to offset any overdue reimbursement amounts against payments owed to Biofrontera AG by the Company
CY2021Q4	BFRI	Contract Asset ContractAsset	-716000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1800000	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1800000	usd
CY2022	us-gaap	Debt Instrument Credit Rating DebtInstrumentCreditRating	Based on a synthetic credit rating of Ba3 and a term of 3.33 to six years, the IBR was determined to be 6% for leased liabilities at inception and 8.5% for 2022 leased liabilities.
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9342000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	12784000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	327000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	100000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	500000	usd
CY2020Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	7602000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1402000	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	6200000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3800000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2400000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3800000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1400000	usd
CY2021Q4	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	12854000	usd
CY2022	BFRI	Fair Value Warrant Issuance Of New Derivative Liabilities FairValueWarrantIssuanceOfNewDerivativeLiabilities	13217000	usd
CY2021	BFRI	Fair Value Warrant Issuance Of New Derivative Liabilities FairValueWarrantIssuanceOfNewDerivativeLiabilities	12261000	usd
CY2022	BFRI	Fair Value Warrant Exercise Of Derivative Liabilities FairValueWarrantExerciseOfDerivativeLiabilities	-6840000	usd
CY2021	BFRI	Fair Value Warrant Exercise Of Derivative Liabilities FairValueWarrantExerciseOfDerivativeLiabilities	-12208000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-16388000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	12801000	usd
CY2022Q4	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	2843000	usd
CY2021Q4	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	12854000	usd
CY2021	BFRI	Revenue From Contract With Customer Allowances And Reserves Provision Related To Current Period RevenueFromContractWithCustomerAllowancesAndReservesProvisionRelatedToCurrentPeriod	637000	usd
CY2021	BFRI	Revenue From Contract With Customer Allowances And Reserves Credit Payments Made During Period RevenueFromContractWithCustomerAllowancesAndReservesCreditPaymentsMadeDuringPeriod	718000	usd
CY2021Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	246000	usd
CY2022	BFRI	Revenue From Contract With Customer Allowances And Reserves Provision Related To Current Period RevenueFromContractWithCustomerAllowancesAndReservesProvisionRelatedToCurrentPeriod	813000	usd
CY2022	BFRI	Revenue From Contract With Customer Allowances And Reserves Credit Payments Made During Period RevenueFromContractWithCustomerAllowancesAndReservesCreditPaymentsMadeDuringPeriod	977000	usd
CY2022Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	82000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	100000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	100000	usd
CY2022Q4	BFRI	Legal Settlements Receivable Percentage LegalSettlementsReceivablePercentage	0.50	pure
CY2021Q4	BFRI	Receivable For Common Stock Warrants Proceeds ReceivableForCommonStockWarrantsProceeds	3258000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	439000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	824000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	85000	usd
CY2021Q4	us-gaap	Deposit Assets DepositAssets	149000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	286000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	756000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	810000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4987000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	710000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	673000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	506000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	406000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	204000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	267000	usd
CY2022	us-gaap	Depreciation Depreciation	100000	usd
CY2021	us-gaap	Depreciation Depreciation	100000	usd
CY2022Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2021Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1568000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1150000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3032000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3450000	usd
CY2022Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17208000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24545000	usd
CY2021Q4	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	47000	usd
CY2022Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	200000	usd
CY2021Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	150000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17408000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24742000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	5100000	usd
CY2021	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	500000	usd
CY2022Q4	BFRI	Legal Settlement Expenses Current LegalSettlementExpensesCurrent	6207000	usd
CY2021Q4	BFRI	Legal Settlement Expenses Current LegalSettlementExpensesCurrent	5625000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2850000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2384000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1353000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	570000	usd
CY2022Q4	BFRI	Accrued Product Revenue Allowances And Reserves AccruedProductRevenueAllowancesAndReserves	82000	usd
CY2021Q4	BFRI	Accrued Product Revenue Allowances And Reserves AccruedProductRevenueAllowancesAndReserves	246000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	372000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	829000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10864000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9654000	usd
CY2021Q4	BFRI	Legal Settlement Expenses LegalSettlementExpenses	5625000	usd
CY2022Q4	BFRI	Other Liability Noncurrent OtherLiabilityNoncurrent	21000	usd
CY2021Q4	BFRI	Other Liability Noncurrent OtherLiabilityNoncurrent	24000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	21000	usd
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	5649000	usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0585	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0009	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.3793	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0103	pure
CY2022	BFRI	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contingent Consideration EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsideration	1.3362	pure
CY2021	BFRI	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contingent Consideration EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsideration	0.0078	pure
CY2022	BFRI	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liabilities EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities	5.7627	pure
CY2021	BFRI	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liabilities EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities	-0.0713	pure
CY2022	BFRI	Effective Income Tax Rate Reconciliation Trueups EffectiveIncomeTaxRateReconciliationTrueups	-0.0742	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-6.8554	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1362	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0585	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0009	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30450000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	24307000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	4824000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	5132000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	96000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	187000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	123000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	103000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	890000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	1693000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	449000	usd
CY2022Q4	BFRI	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	361000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6000	usd
CY2022Q4	BFRI	Deferred Tax Assets Right Of Use Asset DeferredTaxAssetsRightOfUseAsset	-369000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	469000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	36163000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31054000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36163000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31054000	usd
CY2022Q4	BFRI	Legal Settlements Receivable Percentage LegalSettlementsReceivablePercentage	0.50	pure
CY2022	us-gaap	Restructuring Costs RestructuringCosts	0	usd
CY2021	us-gaap	Restructuring Costs RestructuringCosts	800000	usd
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3100000	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	2857143	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4285715	shares
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4600000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	BFRI	Share Exercise Price ShareExercisePrice	5.00
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	8504286	shares
CY2021	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceIssued	5.13
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	4154749	shares
CY2021	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercised	5.09
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4349537	shares
CY2021Q4	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	5.16
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	9273715	shares
CY2022	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceIssued	1.79
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	4426143	shares
CY2022	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercised	1.05
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	9197109	shares
CY2022Q4	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.61
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.55	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.70	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.550	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0134	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0410	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0134	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	617696	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.77
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4082	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.77
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	613614	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.77
CY2022	BFRI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P9Y11M8D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1687000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1290489	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.41
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	166759	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.80
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1737344	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.11
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M7D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	222829000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.27
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y11M26D
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2200000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-640000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-37713000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21139765	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8808233	shares
CY2022	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	12000	usd
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	2000	usd
CY2022	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	358000	usd
CY2021	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	358000	usd
CY2022	us-gaap	Interest Income Related Party InterestIncomeRelatedParty	165000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	10000	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	16000	usd
CY2022	us-gaap	Interest Expense InterestExpense	195000	usd
CY2021	us-gaap	Interest Expense InterestExpense	344000	usd
CY2021	BFRI	Reimbursed Costs ReimbursedCosts	539000	usd
CY2022	BFRI	Other Nonoperating Income Net OtherNonoperatingIncomeNet	33000	usd
CY2021	BFRI	Other Nonoperating Income Net OtherNonoperatingIncomeNet	150000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	689000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.28
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	403628000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	403628000	shares
CY2022	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	option to extend the term of the lease for one five (5) year period
CY2022	us-gaap	Debt Instrument Credit Rating DebtInstrumentCreditRating	Based on a synthetic credit rating of Ba3 and a term of 3.33 to six years, the IBR was determined to be 6% for leased liabilities at inception and 8.5% for 2022 leased liabilities.
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	653000	usd
CY2022	BFRI	Interest On Lease Liabilities InterestOnLeaseLiabilities	99000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	752000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	781000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	234000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M14D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0631	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	565000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	541000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	349000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1455000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	109000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1346000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	498000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	848000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1346000	usd
CY2021Q4	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	22500000	usd
CY2022	us-gaap	Description Of Nature And Effect Of Significant Changes During Period Affecting Comparability DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability	The Company matches 50% of employee contributions up to a maximum of 6% of employees’ salary
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd

Files In Submission

Name	View Source	Status
form10-k.htm	Edgar Link	pending
0001493152-23-007472-index-headers.html	Edgar Link	pending
0001493152-23-007472-index.html	Edgar Link	pending
0001493152-23-007472.txt	Edgar Link	pending
0001493152-23-007472-xbrl.zip	Edgar Link	pending
bfri-20221231.xsd	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
bfri-20221231_cal.xml	Edgar Link	unprocessable
bfri-20221231_def.xml	Edgar Link	unprocessable
bfri-20221231_lab.xml	Edgar Link	unprocessable
bfri-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BFRI
Biofrontera Inc Stock $bfri

2023 Q1 Form 10-K Financial Statement

#000149315223007472 Filed on March 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFRI Biofrontera Inc Stock $bfri

2023 Q1 Form 10-K Financial Statement

#000149315223007472 Filed on March 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFRI
Biofrontera Inc Stock $bfri